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change directed at disease-specific bundling strategies. This study was per-
formed to evaluate rates and predictors of 30-day readmission from a
multicenter trial data set.
Methods: We analyzed the PREVENT III data set of 1404 CLI
patients undergoing LEB at 83 North American centers. The primary end
point was readmission 30 days of discharge. Secondary end points in-
cluded graft patency and limb salvage evaluated in the context of readmis-
sion.
Results: We analyzed 1356 patients, of these, 23 (1.7%) died in-
hospital and were excluded from re-admission analyses. Overall, 327 of 1333
patients (24.5%) were readmitted 30 days of discharge. Reasons for
readmission included 127 (39%) wound infections in the index leg, 75 (23%)
nonvascular reasons, 68 (20.9%) additional procedures in the index leg, and
19 graft failures (5.8%). Univariate predictors are shown in the Table.
Adjusted independent predictors of 30-day readmission included wound
infection (odds ratio [OR], 4.1; 95% confidence interval [CI], 3.0-5.4; P
.0001), renal failure (OR, 4.1; 95% CI, 1.9-8.8; P  .0004), early lost
patency (OR, 1.9; 95% CI, 1.2-2.9; P  .003), dialysis (OR, 1.8; 95% CI,
1.2-2.6; P .003), and female gender (OR, 1.3; 95% CI, 1.0-1.8; P .03).
Patients readmitted 30 days had lower rates of limb salvage at 1 year
(78%  2.4% vs 91%  0.9%, P  .0001). Thirty-day readmission was
predictive of limb loss (HR, 2.25; 95% CI, 1.6-3.1; P  .0001) at 1 year,
after adjustment for other factors.
Conclusions: Readmission after LEB for CLI is common (24%) and
associated with defined clinical predictors. Readmission is associated with
long-term limb loss. These data provide benchmark values for this complex
patient population and may prove useful as disease-specific bundling strate-
gies are derived.





Pre-op factors, No. (%)
Female gender 333 (33.1) 142 (43.4) .0008
Dialysis dependence 109 (10.9) 52 (15.9) .02
Tissue loss indication 733 (72.9) 255 (78.0) .05
Post-op factors
Length of stay, mean
[SD] days
8.4 [8.9] 9.7 [9.1] .0009
Wound infection,
No. (%)
140 (13.9) 133 (40.7) .0001
Acute renal failure,
No. (%)
15 (1.5) 17 (5.2) .0005
Early graft-related
event, No. (%)
76 (7.5) 44 (13.5) .002
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Introduction and objectives: This study reports the 2-year diameter
and volume data for abdominal aortic aneurysms (AAAs) treated in the U.S.
pivotal clinical trial of the Endurant Stent Graft System.
Methods: From April 2008 to May 2009, 150 patients were treated
with the Endurant stent graft as part of a prospective multicenter trial. The
main inclusion criteria were AAA diameter 5 cm, neck length 10 mm,
and neck angulation 60°. A core laboratory reviewed all imaging. Expan-
sion was defined as 5 mm diameter or 5% by 3-dimenional volume.
Results: Stent graft implant was successful in 149 of 150 patients. The
6-month volume results were nearly identical to the 24-month diameter
results, and all AAAs identified with expansion by diameter at 24 months had
expansion by volume criteria (but not diameter) at 6 and 12 months.
Change in AAA size was more likely to be identified by volume at all time
points, with13% of AAAs classified as “no change” by volume criteria at 1
and 2 years (P  .05). Most AAAs classified as “no change” by diameter
criteria were shrinking by volume criteria. Secondary intervention for en-
doleak occurred in five patients, all suspected type II endoleak. All were
identified as expanding earlier by volume, including two ultimately identi-
fied to be a type I endoleak. There were no ruptures or aneurysm-related
deaths.
Conclusions: Midterm results of the Endurant pivotal trial are good,
with low expansion rates at 2 years, even by volume criteria. Three-
dimensional volume detects aneurysm shrinkage and expansion on average
18 months sooner than diameter, allowing for earlier reassurance in most
patients and earlier intervention in the small minority who need it.
Table. AAA outcomes over time
Outcome Decrease (%) No change (%) Increase (%)
Diameter
6 mon 31 69 0
12 mon 47 53 0
24 mon 63 35 2
Volume
6 mon 63 34 4
12 mon 79 13 7
24 mon 78 12 10
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Introduction and objectives: It has been suggested that long-term
use of warfarin can affect the durability of endovascular aneurysm repair
(EVAR) by continued sac expansion, possible rupture, and the need for
further surgical interventions. The purpose of this study was to determine
whether chronic anticoagulation therapy with warfarin is associated with an
increased risk of rupture or need for reintervention after EVAR.
Methods: We reviewed the records of 401 consecutive patients who
underwent EVAR at a single institution from 2003 until 2011. Patients on
warfarin were compared with a control group not anticoagulated. Primary
end points were rupture, explant, reintervention, death, and a composite
outcome if any of these occurred. The presence of an endoleak at last
follow-up and change in aneurysm sac size of 5 mm were secondary end
points. Cox proportional hazards models were used to estimate the effect of
warfarin use on the primary and secondary outcomes, controlling for age,
sex, obesity, specific comorbidities, antiplatelet drugs, statin use, and ur-
gency of EVAR.
Results:Of 401 patients, 363 (90.5 %) with a median follow-up period
of 29 months had sufficient data for analysis. Warfarin use was not associated
with an increased risk of any of the primary or secondary end points (Table).
After controlling for covariates and length of observation via Cox propor-
tional hazards models, we found the effect of warfarin remained insignifi-
cant. There was an increased in endoleak rate and adverse outcomes after
emergency EVAR and in those patients deemed unfit for open surgical
repair.
Conclusions: Chronic oral anticoagulation with warfarin does not
appear to affect the incidence of endoleak after EVAR or the need for




Death, Explant, Reintervention, Any of these,
No. (%) No. (%) No. (%) No. (%)
Warfarin 68 7 (10) 3 (4) 6 (9) 16 (24)
No warfarin 295 35 (12) 5 (2) 25 (8.5) 65 (22)
P NS NS NS NS
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Introduction and objectives: We recently reported improved early
mortality and paraplegia rates in a small cohort of patients with type I-III
thoracoabdominal aortic aneurysms (TAA) treated with atrio-femoral by-
pass (AFB) and motor-evoked potentials (MEVP) when compared with a
propensity-matched cohort of patients treated with the clamp-and-sew
method (CS). The use of AFB/MEVP increases the level of complexity of
TAA repair, and it is unclear if the early benefits will be sustained when this
is applied to a general population with type I-III TAA, which is the goal of
this study.
Methods: Consecutive patients undergoing repair of nonruptured
Crawford extent I-III TAA from January 1987 to December 2011 were
identified. Patients were stratified according to operative approach (AFB/
MEVP vs CS). End points included long-term survival and the composite
outcome of perioperative death and paraplegia. A multivariate, risk-adjusted
JOURNAL OF VASCULAR SURGERY
November 20121480 Abstracts
